Merck and Daiichi Sankyo Report the P-III (HERTHENA-Lung02) Study Data of Patritumab Deruxtecan to Treat Non-Small Cell Lung Cancer
Shots:
- The P-III (HERTHENA-Lung02) study is assessing patritumab deruxtecan (5.6mg/kg, Q3W) vs 4 cycles of pemetrexed + Pt-based CT to treat EGFR-mutated metastatic or locally advanced NSCLC patients (n=586) failed on 3rd-gen. EGFR TKI therapy
- Study reached its 1EP, depicting improved PFS; OS was not mature, its evaluation continues. Safety aligned with the prior studies, with most ILD events being grade 1 & 2 & two being grade 5. Data will be highlighted at future conferences & shared with regulatory authorities
- Patritumab deruxtecan is an HER3-directed ADC jointly developed by Daiichi Sankyo & Merck. It contains a human anti-HER3 IgG1 mAb combined with a topoisomerase I inhibitor payload via cleavable linkers
Ref: Merck | Image: Merck & Daiichi Sankyo
Related news:- Daiichi Sankyo Presents P-II Trial (HERTHENA-Lung01) Results of Patritumab Deruxtecan for EGFR-Mutated Metastatic NSCLC at WCLC 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
